The neuro®bromatosis 2 (NF2) tumor suppressor gene encodes an intracellular membrane-associated protein, called merlin (or schwannomin), that belongs to the band 4.1 family of cytoskeleton-associated proteins. Inactivating NF2 mutations occur in several sporadic tumor types and have been linked to the NF2 disease, whose hallmark is the development of bilateral Schwann cell tumors (schwannomas) of the eighth cranial nerve. Two major alternatively spliced NF2 variants are expressed in normal tissues:`NF2-17' lacking exon 16 and`NF2-16' that contains exon 16 and encodes a merlin protein truncated at the C-terminus. We report that overexpression of NF2-17 in rat schwannoma cells inhibits their growth in vitro and in vivo, while NF2-16 fails to in¯uence schwannoma growth. Tumor growth inhibition by merlin depends on an interdomain association occurring either in cis or in trans between the N-and C-termini. This association does not occur in the truncated NF2-16 protein nor in a mutant NF2-17 protein lacking C-terminal sequences. These data indicate that merlin has a unique mechanism of tumor suppression, inhibiting cell proliferation via self-association.
Neuro®bromatosis type 2 (NF2) is an autosomal dominant disease that aects approximately one in 40 000 individuals worldwide. The chief diagnostic feature of NF2 is the development of bilateral vestibular Schwann cell tumors (schwannomas). In addition, aected individuals often manifest with meningiomas, spinal schwannomas, and subcapsular lens opacities . The vestibular schwannomas associated with NF2 can cause severe functional impairments including deafness and balance disorder as a result of nerve compression by enlarging tumors. The management of NF2 is challenging, since surgical removal of these tumors can lead to permanent nerve damage and signi®cant patient morbidity.
The NF2 gene maps to chromosome 22q and encodes a protein called merlin (or schwannomin) which belongs to the band 4.1 family of actin cytoskeleton-associated proteins (Trofatter et al., 1993; Rouleau et al., 1993) . Among the members of this family, merlin shares striking amino acid homology (approximately 63%) with the N-termini of ezrin, radixin and moesin (ERM proteins). The C-terminal half of merlin and the ERM proteins share a similar alpha helical region. The extreme C-terminus of merlin, however, is unique and lacks the actin binding domain present in some of the ERM proteins. In addition, merlin can have two dierent charged C-termini resulting from alternative splicing Haase et al., 1994; Hara et al., 1994; Gutmann et al., 1995) . These forms of NF2 are referred to as isoform I' or`NF2-17', lacking exon 16 and`isoform II' or`NF2-16', which contains exon 16. The inclusion of exon 16 inserts 11 unique C-terminal amino acids followed by a termination codon that prevents translation of exon 17.
In addition to tumors from NF2 patients, inactivating mutations in both NF2 alleles occur in the majority of sporadic schwannomas and in other tumor types, including mesotheliomas Ruttledge et al., 1994; Sainz et al., 1994; Bianchi et al., 1995) . Studies using merlin-speci®c antibodies have indicated that merlin is localized at or near the plasma membrane and may be associated with the cytoskeleton (den Bakker et al., 1995; Gonzalez-Agosti et al., 1996; Scherer and Gutmann, 1996) . Merlin is therefore a non-nuclear tumor suppressor protein that likely in¯uences cellular signaling at the membrane or along particular signal transduction pathways (for review see Gutmann, 1995) . Elucidating how merlin functions as a negative growth regulator is essential for understanding its contribution to tumorigenesis.
In order to characterize how merlin in¯uences schwannoma growth and to determine which domains of merlin are crucial for tumor suppression, we examined the eects of NF2-17 overexpression on schwannoma growth using the RT4-D6P2T and JS1 rat schwannoma cell lines (Schubert et al., 1974; Tomozawa and Sueoka, 1978) which express little endogenous merlin (Figure 1a ). Cells were transfected with an expression vector either containing or lacking the NF2-17 cDNA. Stable clones expressing the NF2-17 variant at levels 8 ± 10-fold higher than the endogenous protein were selected for comparison to clones transfected with vector alone (Figure 1a Figure  1b ). These cells were viable and did not incorporate more Trypan blue than vector controls (data not shown). Based on FACS analysis of propidium iodidelabeled nuclei, 32% of RT4-D6P2T cells transfected with vector alone and grown in 2% fetal bovine serum were in the G0/G1 phase of the cell cycle while 71% of cells overexpressing NF2-17 were in G0/G1. Dierences in [ 3 H]thymidine incorporation were therefore likely due to cell cycle alterations and not increased cell death. To determine whether NF2-17 in¯uences schwannoma growth in vivo, JS1 or RT4-D6P2T clones overexpressing NF2-17 were subcutaneously injected into nude mice and their tumor volumes were measured every 4 days. Tumors from cells overexpressing NF2-17 grew 3 ± 4 times slower than vector controls (Figure 1c ). These data indicate that NF2-17 inhibits schwannoma growth both in vitro and in vivo. 
Figure 1 NF2-17 but not NF2-16 or truncated NF2-17 inhibit schwannoma growth in vitro and in vivo. (a) Western blot analysis (see Figure 3 ) of RT4-D6P2T cells stably transfected with NF2-17, NF2-16 or NF2-trunc using an anti-N-terminal merlin antibody (Scherer and Gutmann, 1996; Gutmann et al., 1997) . The NF2-17 and NF2-16 sequences were generated by RT ± PCR, sequenced, and cloned into pcDNA3 (G418 resistance; Invitrogen) either with or without sequences encoding the FLAG epitope (recognized by antibody M2 from Kodak) at the 5' end of the gene. Truncated NF2-17 was generated by StuI ± EcoRV endonuclease digestion followed by ligation into full length constructs. Cells were grown as previously described (Sherman et al., 1995) and transfected with plasmid DNA using DOTAP (Boehringer Mannheim) according to the manufacturer's instructions. Stable clones were selected with 500 mg/ml of active G418. Clones expressing the dierent NF2 constructs were selected with similar levels of protein expression, 8 ± 10-fold above endogenous levels as determined by scanning densitometry. Among alternatively spliced forms of NF2, NF2-16 is the most consistently detected splice variant in tumors and normal tissues Haase et al., 1994; Hara et al., 1994; Gutmann et al., 1995) . Unlike NF2-17, this truncated merlin protein is predicted to have a hydrophilic non-helical Cterminus. To determine whether NF2-16 can also in¯uence schwannoma growth, we established stable clones of RT4-D6P2T cells expressing NF2-16 at levels comparable to NF2-17 expression in the clones described above (Figure 1a ). Compared to vector controls, representative clones overexpressing NF2-16 showed no dierences in their growth rates in vitro or in vivo (Figure 1b and d) . Similar results were obtained in cells overexpressing a mutant of NF2-17 truncated at amino acid 547 (`NF2-trunc'; Figure 1b ) and in cells overexpressing radixin (data not shown). These data indicate that merlin proteins lacking extreme Cterminal sequences cannot suppress schwannoma growth and demonstrate functional dierences between the two NF2 splice variants.
Since disrupting the C-terminus of merlin interferes with merlin's growth inhibitory activity, we tested whether the C-terminus alone is sucient to inhibit schwannoma cell proliferation. RT4-D6P2T cells were stably transfected with constructs encoding the C-terminal half of merlin (`C17', amino acids 299 ± 595), the C-terminus containing the sequences encoded by exon 16 (`C16'), or the N-terminus (amino acids 1 ± 302), then selected as described above. None of these constructs in¯uenced schwannoma proliferation either in vivo (data not shown) or in vitro (Figure 2a ), indicating that neither the Cnor the N-terminus of merlin alone are sucient to inhibit cell growth.
The N-termini of radixin and ezrin can exert a regulatory in¯uence over their C-termini either in cis or in trans Martin et al., 1995) via an intramolecular association (Gary and Bretscher, 1995; Magendantz et al., 1995) . We tested whether such interactions are required for the growth inhibiting functions of merlin by stably transfecting RT4-D6P2T cells with both NF2-N and NF2-C17 using dierent selectable markers. Representative clones overexpressing similar amounts of the N-and C17-terminal merlin fragments were growth inhibited up to 50% compared to cells expressing either terminus alone or vector controls (Figure 2b ). The N-and C-termini of the NF2-17 merlin variant can therefore inhibit cell growth by acting in cis (i.e. the complete protein) or in trans, consistent with the notion that interdomain interactions are crucial for merlin's function.
To determine if merlin is capable of intramolecular binding, we tested whether an N-terminal merlin-GST fusion protein (`NF2.400', containing amino acids 9 ± 400 of merlin) could bind in vitro translated C17 terminal sequences. As shown in Figure 3a , 46% of the merlin C17 protein bound to the N-terminal-GST fusion protein as determined by scanning densitometry, compared to C16 and truncated C17 with 9% and 1% binding, respectively. An unrelated protein sequence (NF1-GRD) also failed to bind to merlin-GST (1 ± 3% bound; data not shown). To verify that these interactions occur in live cells, NF2-C17 or C16 were co-transfected into COS-1 cells with NF2-N. Proteins were immunoprecipitated using either C17-or C16-speci®c antibodies, then assayed by Western blotting for N-terminal sequences using an N-terminal speci®c antibody. Equal amounts of C16 and C17 were immunoprecipitated as detected by Western blot using FLAG and merlin isoform-speci®c antibodies (data not shown). The merlin N-terminus co-immunoprecipitated with the C17 protein, but not the C16 protein ( Figure  3b ). Furthermore, under non-reducing conditions, Nand C-17 terminal speci®c antibodies recognized bands at 33 kDa and at 66 kDa (the combined size of both halves of merlin) in lysates of RT4-D6P2T cells cotransfected with NF2-C17 and NF2-N, suggesting that the N-and C17-termini can form complexes (data not Figure 2 Mean CPMs and standard errors of the mean from [ 3 H]thymidine incorporation assays of RT4-D6P2T clones expressing merlin fragments. The N-terminal (residues 1 ± 302), and C-terminal (residues 299 ± 595 with or without exon 16) sequences were cloned into pcDNA3 as described above. The Nterminal sequence was also cloned into pCEP4 (Hygromycin resistance; Invitrogen). (a) Cells were transfected with either pcDNA3 alone or pcDNA3 carrying the NF2 constructs shown. (b) Cells were co-transfected with pCEP4-N terminus and pcDNA3-C17. Vector controls included cells transfected with both empty pcDNA3 and pCEP4. The combined overexpression of the N-terminus with the C17 terminus of NF2 inhibited growth by up to 50% compared to cells expressing the empty vectors, while the N-, C17-or C-16-terminus alone had no eect on cell growth. Data were analysed via a two-tailed t-test, with a P value of 0.005 or less considered signi®cant shown). No higher molecular weight bands were observed in lysates of cells overexpressing either half of merlin alone. These experiments collectively argue that the N-and C17 termini of merlin bind to each other, and that this binding depends on the presence of extreme C-terminal protein sequences encoded by exon 17.
Previous studies indicated that NF2-17 can inhibit NIH3T3 cell proliferation in vitro (Tikoo et al., 1994; Lutchman and Rouleau, 1995) . In this report, we have shown that NF2-17 also inhibits schwannoma growth both in vitro and in vivo, consistent with the idea that NF2 functions as a negative growth regulator in Schwann cells. We have identi®ed functional differences between the two major NF2 variants and found that growth inhibition is only achieved by merlin proteins with N-and C-terminal sequences that permit interdomain binding. The ®nding that NF2-16 lacks growth suppressor activity is intriguing, since the ratios of NF2-17 and NF2-16 change during nervous system development . Ratios between merlin variants could therefore conceivably mediate dierent merlin functions.
Since cell growth is inhibited by co-expression of the merlin N-and C17 termini, but not by either terminus alone, we propose that merlin self-association is a prerequisite for its tumor suppressor activity. We did not detect endogenous or overexpressed merlin proteins forming dimers or multimers. It is possible, however, that such complexes exist only transiently, are not easily detected, or only form under speci®c conditions in vivo.
Our model predicts that patients with NF2 mutations causing merlin truncations would have compromised tumor suppression due to abrogated N-and Cterminal association, whereas interdomain binding might only be mildly aected in patients with missense mutations. Indeed, patients with frameshift and nonsense mutations typically present with more clinically severe disease (i.e. early onset and multiple tumors), while patients with single codon alterations often have only mild phenotypes (MacCollin et al., The N-terminus of merlin binds to the C17-but not the C-16 terminus. (a) Binding assay of in vitro translated merlin Ctermini to an immobilized N-terminal-GST fusion protein. B=bound, S=supernatant. GST.NF2-400 was constructed using a PCR fragment corresponding to residues 9 ± 400 of the full length NF2 cDNA (the generous gift of J Gusella and V Ramesh) cloned into pGEX-2T (Pharmacia). Fusion protein was puri®ed on glutathione-agarose beads (Swaeld and Johnston, 1996 then equal amounts of GST alone or GST-NF2.400 were incubated with in vitro translated 35 S-methionine-labeled NF2 C-terminal products for 2 h at 48C. Beads were washed four times in TEN buer (10 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100), eluted with Laemmli buer (Laemmli, 1970) , then separated by SDS ± PAGE for analysis by autoradiography. Forty-six percent of the C17 protein bound to the N-terminus (`NF2.400')-GST fusion protein compared to GST alone (1% bound), while neither the truncated (`C-trunc') nor C16 proteins demonstrated any signi®cant binding. Only 1% of the C-trunc bound to the GST-NF2.400 fusion protein compared to 1.5% binding to GST alone. Nine percent of the C16 bound to the GST-NF2.400 fusion protein compared to 3% binding to GST alone. Percent binding was calculated by scanning densitometry using NIH-Image 1.55 software. Similar binding percentages were observed in other experiments. (b) COS-1 cells were transiently transfected with combinations of pcDNA3 vector, pcDNA3-N-terminal (N), pcDNA3-C17, and pcDNA3-C16 for 2 days. Proteins were then immunoprecipitated from precleared lysates in NP-40 buer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl¯uoride, 10 mg/ml leupeptin) by incubation with a 1 : 100 dilution of merlin C17-or C16-terminal-speci®c antibodies overnight at 48C, followed by incubation with Protein A Sepharose beads. After the beads were washed 4 ± 5 times in NP40 lysis buer, proteins were eluted in Laemmli buer, and analysed by Western blotting with an N-terminal antibody (left panel; see Scherer and Gutmann, 1996; Gutmann et al., 1997 for details of the antibody preparation). The N-terminal protein was only co-immunoprecipitated with C17 protein and not C16. To con®rm expression of all transfected proteins, aliquots of lysates from transfected cells were analysed by Western blotting using the anti-FLAG (M2) antibody (right panel) and merlin-speci®c antibodies (not shown) as previously described (Scherer and Gutmann, 1996) . All immunoprecipitates were also Western blotted with FLAG and merlin isoform-speci®c antibodies to demonstrate equal expression and immunoprecipitation of merlin C-terminal fragments (data not shown) 1994; Sainz et al., 1994; Evans et al., 1995; Bijisma et al., 1995; Parry et al., 1996) . Identifying NF2 mutations resulting in aberrant merlin self-association could, therefore, be of signi®cant diagnostic and prognostic value.
